Associations of plasma pentraxin 3 and monocyte chemoattractant protein-1 concentrations with cardiovascular disease in patients with chronic kidney disease

Renal Failure

Volumn 33, Issue 4, 2011, Pages 398-404

  Nishi, Keiko ^a,b   Imamura, Takuroh ^a   Kitamura, Kazuo ^a   Ogawa, Tsuneo ^c   Fujimoto, Shouichi ^b   Kakitsubata, Yousuke ^d   Ishikawa, Tadashi ^d   Asada, Yujiro ^e   Kodama, Tatsuhiko ^f  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b UNIVERSITY OF MIYAZAKI HOSPITAL   (Japan)

^c MINAMI KYUSHU UNIVERSITY   (Japan)

^d Miyazaki Konan Hospital   (Japan)

^e UNIVERSITY OF MIYAZAKI   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

cardiorenal syndrome; cardiovascular disease; Chronic kidney disease; monocyte chemoattractant protein 1; pentraxin 3

Indexed keywords

C REACTIVE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTRAXIN 3; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIATOR; PRIORITY JOURNAL;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHEMOKINE CCL2; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; SERUM AMYLOID P-COMPONENT;

EID: 79955572793     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.568136     Document Type: Article

References (33)

1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circula-tion. 2003;108:2154-2169. (Pubitemid 37337595)
2. Roberts MA, Hare DL, Ratnaike S, Ierino FL. Cardiovascular biomarkers in CKD: Pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis. 2006;48:341-360. (Pubitemid 44262433)
3. Menon V, Greene T, Wang X, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int. 2005;68:766-772. (Pubitemid 43323132)
4. Mantovani A, Garlanda C, Doni A, Bottazzi B. Pentraxins in innate immunity: From C-reactive protein to the long pentraxin PTX3. J Clin Immunol. 2008;28:1-13.
5. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337-366. (Pubitemid 40563173)
6. Introna M, Alles VV, Castellano M, et al. Cloning of mouse PTX3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood. 1996;87:1862-1872. (Pubitemid 26068902)
7. Alles VV, Bottazzi B, Peri G, Golay J, Introna M, Mantovani A. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood. 1994;84:3483-3493. (Pubitemid 24352913)
8. Peri G, Introna M, Corradi D, et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102:636-641. (Pubitemid 30640663)
9. Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2007;27:161-167. (Pubitemid 46360394)
10. Kotooka N, Inoue T, Fujimatsu D, et al. Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thick-ening. Atherosclerosis. 2008;197:368-374. (Pubitemid 351273259)
11. Suliman ME, Yilmaz MI, Carrero JJ, et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:976-985.
12. Boehme M, Kaehne F, Kuehne A, et al. Pentraxin 3 is elevated in hemodialysis patients and is associated with cardio-vascular disease. Nephrol Dial Transplant. 2007;22:2224-2229. (Pubitemid 47244700)
13. Tong M, Carrero JJ, Qureshi AR, et al. Plasma pentraxin 3 in patients with chronic kidney disease: Associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol. 2007;2:889-897.
14. Leonard EJ, Yoshimura T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today. 1990;11:97-101. (Pubitemid 20062717)
15. Rollins BJ, Yoshimura T, Leonard EJ, Pober JS. Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am J Pathol. 1990;136:1229-1233. (Pubitemid 20210321)
16. Sica A, Wang JM, Colotta F, et al. Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor. J Immunol. 1990;144:3034-3038. (Pubitemid 20149476)
17. Reape TJ, Groot PH. Chemokines and atherosclerosis. Athero-sclerosis. 1999;147:213-225. (Pubitemid 29512252)
18. Hojo Y, Ikeda U, Takahashi M, Shimada K. Increased levels of monocyte-related cytokines in patients with unstable angina. Atherosclerosis. 2002;161:403-408. (Pubitemid 34219194)
19. de Lemos JA, Morrow DA, Sabatine MS, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coro-nary syndromes. Circulation. 2003;107:690-695. (Pubitemid 36222595)
20. Stinghen AE, Goncalves SM, Martines EG, et al. Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin Pract. 2009;111:c117-c126.
21. Papayianni A, Alexopoulos E, Giamalis P, et al. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in hemodialysis patients: Association with inflammation, dyslipi-daemia, and vascular events. Nephrol Dial Transplant. 2002;17:435-441. (Pubitemid 34211140)
22. Imai E, Horio M, Watanabe T, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:621-630.
23. Nauta AJ, de Haij S, Bottazzi B, et al. Human renal epithelial cells produce the long pentraxin PTX3. Kidney Int. 2005;67:543-553. (Pubitemid 40139846)
24. Bussolati B, Peri G, Salvidio G, Verzola D, Mantovani A, Camussi G. The long pentraxin PTX3 is synthesized in IgA glomerulonephritis and activates mesangial cells. J Immunol. 2003;170:1466-1472. (Pubitemid 36139516)
25. Mantovani A, Garlanda C, Bottazzi B, et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol. 2006;45:326-330. (Pubitemid 44765293)
26. Bottazzi B, Garlanda C, Salvatori G, Jeannin P, Manfredi A, Mantovani A. Pentraxins as a key component of innate immunity. Curr Opin Immunol. 2006;18:10-15. (Pubitemid 43049642)
27. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002;22:e10-e14.
28. Savchenko A, Imamura M, Ohashi R, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol. 2008;215:48-55. (Pubitemid 351619875)
29. Klouche M, Peri G, Knabbe C, et al. Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis. 2004;175:221-228. (Pubitemid 38942901)
30. Camozzi M, Zacchigna S, Rusnati M, et al. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol. 2005;25:1837-1842. (Pubitemid 41243451)
31. Napoleone E, Di Santo A, Bastone A, et al. Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: A novel link between vascular inflammation and clotting activation. Arterioscler Thromb Vasc Biol. 2002;22:782-787. (Pubitemid 34517789)
32. Egashira K:. Molecular mechanisms mediating inflammation in vascular disease: Special reference to monocyte chemoat-tractant protein-1. Hypertension. 2003;41:834-841. (Pubitemid 36314600)
33. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998;2:275-281. (Pubitemid 128373654)